Principal Financial Group Inc. Boosts Stake in Pediatrix Medical Group, Inc. (NYSE:MD)

Principal Financial Group Inc. raised its holdings in Pediatrix Medical Group, Inc. (NYSE:MD) by 6.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 586,190 shares of the company’s stock after purchasing an additional 34,266 shares during the quarter. Principal Financial Group Inc. owned 0.68% of Pediatrix Medical Group worth $8,494,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Victory Capital Management Inc. raised its holdings in shares of Pediatrix Medical Group by 95.8% in the 4th quarter. Victory Capital Management Inc. now owns 76,553 shares of the company’s stock valued at $1,004,000 after buying an additional 37,463 shares during the period. Proficio Capital Partners LLC purchased a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at $404,000. Raymond James Financial Inc. purchased a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at $3,066,000. Amundi raised its holdings in shares of Pediatrix Medical Group by 199.7% in the 4th quarter. Amundi now owns 40,954 shares of the company’s stock valued at $521,000 after buying an additional 27,288 shares during the period. Finally, AlphaQuest LLC raised its holdings in shares of Pediatrix Medical Group by 65.9% in the 4th quarter. AlphaQuest LLC now owns 5,066 shares of the company’s stock valued at $66,000 after buying an additional 2,012 shares during the period. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. UBS Group cut their price objective on Pediatrix Medical Group from $18.50 to $16.00 and set a “neutral” rating on the stock in a report on Monday, May 12th. Truist Financial cut their price objective on Pediatrix Medical Group from $18.00 to $16.00 and set a “hold” rating on the stock in a report on Friday, April 11th. Finally, Macquarie boosted their price objective on Pediatrix Medical Group from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $16.67.

Pediatrix Medical Group Trading Up 0.2%

MD opened at $13.15 on Tuesday. Pediatrix Medical Group, Inc. has a 12 month low of $6.96 and a 12 month high of $17.67. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -13.01, a PEG ratio of 0.88 and a beta of 1.25. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.81 and a quick ratio of 1.81. The business has a fifty day moving average price of $13.96 and a 200 day moving average price of $13.89.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Tuesday, May 6th. The company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.25 by $0.08. Pediatrix Medical Group had a positive return on equity of 17.43% and a negative net margin of 4.17%. The firm had revenue of $458.36 million during the quarter, compared to analysts’ expectations of $451.44 million. During the same period in the previous year, the firm posted $0.20 EPS. Pediatrix Medical Group’s revenue for the quarter was down 7.4% on a year-over-year basis. Sell-side analysts expect that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.